Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) Operating Margin: 2020-2024

Historic Operating Margin for Fulcrum Therapeutics (FULC) over the last 4 years, with Jun 2024 value amounting to 65.61%.

  • Fulcrum Therapeutics' Operating Margin rose 316698.00% to 65.61% in Q2 2024 from the same period last year, while for Jun 2024 it was -39.72%, marking a year-over-year increase of 349495.00%. This contributed to the annual value of -27.37% for FY2024, which is 391787.00% up from last year.
  • Fulcrum Therapeutics' Operating Margin amounted to 65.61% in Q2 2024, which was up 102.04% from -3,213.78% recorded in Q4 2023.
  • In the past 5 years, Fulcrum Therapeutics' Operating Margin registered a high of 65.61% during Q2 2024, and its lowest value of -9,471.19% during Q1 2023.
  • For the 3-year period, Fulcrum Therapeutics' Operating Margin averaged around -3,144.50%, with its median value being -3,101.36% (2023).
  • As far as peak fluctuations go, Fulcrum Therapeutics' Operating Margin crashed by 846,818bps in 2023, and later skyrocketed by 316,698bps in 2024.
  • Fulcrum Therapeutics' Operating Margin (Quarterly) stood at -420.99% in 2020, then crashed by 4,478bps to -465.78% in 2021, then crashed by 361,787bps to -4,083.65% in 2022, then skyrocketed by 86,987bps to -3,213.78% in 2023, then soared by 316,698bps to 65.61% in 2024.
  • Its Operating Margin was 65.61% in Q2 2024, compared to -3,213.78% in Q4 2023 and -3,615.28% in Q3 2023.